Helping NASH Study Sites to Succeed: Insights into Operational Best Practices

Life Sciences, Clinical Trials, Patient Recruitment & Retention, Drug Discovery & Development,
  • Thursday, December 10, 2020 | 11am EST (NA) / 4pm GMT (UK) / 5pm CET (EU-Central)
  • 60 min

Non-alcoholic steatohepatitis (NASH) is a complicated disease that requires expertise across a broad spectrum of therapeutic areas, including hepatology, gastroenterology and endocrinology. As the prevalence of NASH continues to rise and the number of clinical trials is increasing, there is greater demand for patients and increased competition for site resources. In this challenging landscape, how can pharma and biotech companies ensure that their NASH trial sites are set up for success and best supported to drive the development of new therapies? We will provide perspectives on how to best partner with sites now and in the future to meet the growing demand for NASH patients while delivering high quality results.

Get insights and feedback from our extensive NASH study experience, and the findings from ICON’s recent survey of more than 2,000 sites across 30 countries. We will discuss the operational data compiled and shared through questionnaire responses on best practices for NASH study sites.

Speaker

http://Debbie%20Marshall,%20ICON%20plc

Debbie Marshall, Program Manager, Clinical Project Management, Cardiovascular/Metabolic Therapeutics. ICON plc

Debbie Marshall has significant NASH experience, including seven NASH studies over the past five years, enrolling 888 patients in eight countries (US, CAN, UK, France, Germany, Italy, New Zealand, and Spain). Through her extensive NASH experience, Debbie maintains relationships with many US, UK, German, and Canadian NASH investigators. Additionally, she has collaborated with radiology and histopathology central readers, fostering key relationships throughout the NASH community.

Message Presenter

Who Should Attend?

This program is intended for professionals from NASH pharmaceutical, biotech, and medical device companies involved in:

  • NASH Clinical Development
  • Patient Recruitment
  • Site Management
  • Imaging

What You Will Learn

Participants will gain insights on:

  • How to best support global NASH sites to succeed in a competitive environment
  • Optimising the operational strength of study sites to collectively support the NASH pipeline
  • How understanding global and regional nuances can enhance NASH site patient recruitment and operational strategy

Xtalks Partner

ICON plc

ICON plc is a global provider of outsourced drug and device development and commercialization services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently operates from 98 locations in 40 countries and has approximately 15,200 employees.

Media Partner

The original site for employees in the pharma, medical, diagnostic and related industries. Our hand-curated daily news feed and active message forums will keep you informed. 

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account